The US Supreme Court case involved pro-life medical associations and doctors seeking to rescind FDA approval of the drug mifepristone, used in abortion. The FDA initially approved the drug in 2000 with restrictions, which were relaxed in 2016 and 2021. The plaintiffs argued against the FDA’s actions, but the Court ruled they lacked standing due to the lack of a direct injury caused by the FDA’s actions. The Court emphasized that federal courts are not for general complaints about government actions, suggesting alternative avenues for the plaintiffs to address their concerns. Ultimately, the Supreme Court reversed the appeals court’s judgment.
Source link
US Supreme Court decision on challenge to mifeprostone
